(PharmaNewsWire.Com, November 04, 2017 ) According to Publisher, the Global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market is expected to grow from $202.12 million in 2016 to reach $1,350.23 million by 2023 with a CAGR of 31.2%. Rising demand for noninvasive diagnostic tools matched with growing levels of patient awareness is likely to augment the growth of NASH biomarkers market over the forecast period. Furthermore, growing prevalence of chronic liver conditions is expected to upsurge demand for noninvasive diagnostic tools. On the contrary, huge price and invasiveness, ensued in changing the taste for noninvasive biomarkers is expected to limit the market growth over the forecast period.
Biomarkers are commonly proteins detected in the blood, urine or other body fluids that are either raised by the tumor itself. Serum Biomarker should be measured at a low cost, by a widely usable assay with reproducible outcomes in a specimen that is comfortable to access. The serum biomarkers have the ability to deliver efficient results. Apoptosis markers follow this lead closely. Hospitals and diagnostic laboratories are likely to be rising in requirement for non-invasive NASH diagnostic and monitoring instruments at the ongoing tests by pharmaceutical manufacturers and CRO. North America holds the largest market share due to different reasons like rising prevalence of infectious diseases, cardiovascular diseases & cancer, rising R&D activities from key players, and favorable government initiatives. Asia Pacific is expected to become the fastest growing market owing to enlargement of key market participants. There is a substantial rise in R&D spending for biomarkers from the countries like China, India and Japan. In addition, increasing demand for biomarkers among end-users and rising number of CROs are factors favoring the market growth in this region. Some of the key players in global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market include Allergan Plc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Dainippon Sumitomo Pharma (DSP), Enzo Biochem, GENFIT SA, Gilead Sciences, Inc. (GILD), Intercept Pharmaceuticals, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Prometheus Laboratories Corp, Raptor Pharmaceutical Corp and Siemens Heathcare Pvt. Ltd.
Regions Covered: -North America US Canada Mexico -Europe Germany UK Italy France Spain Rest of Europe -Asia Pacific Japan China India Australia New Zealand South Korea Rest of Asia Pacific -South America Argentina Brazil Chile Rest of South America -Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
Company Profiling 9.1 Allergan Plc 9.2 AstraZeneca 9.3 Boehringer Ingelheim 9.4 Bristol-Myers Squibb Company 9.5 Dainippon Sumitomo Pharma (DSP) 9.6 Enzo Biochem 9.7 GENFIT SA 9.8 Gilead Sciences, Inc. (GILD) 9.9 Intercept Pharmaceuticals 9.10 Novartis AG 9.11 Novo Nordisk A/S 9.12 Pfizer Inc 9.13 Prometheus Laboratories Corp 9.14 Raptor Pharmaceutical Corp 9.15 Siemens Heathcare Pvt. Ltd.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
